Completed
PHASE3
INTERVENTIONAL
NCT04093752
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main reason for this study is to compare the study drug tirzepatide to insulin glargine in participants with type 2 diabetes on metformin with or without a sulfonylurea.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Name:
Insulin Glargine
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
TimeFrame:
Baseline, Week 40
Description:
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with covariates Baseline + Country + Baseline Oral Antihyperglycemic Medication (OAM) Use (Metformin (Met), Met plus Sulfonylurea (SU)) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Trial Information
NCT ID
NCT04093752
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025